Key result
Sodium-glucose cotransporter 2 inhibitors demonstrated significant benefits in reducing cardiovascular death or hospitalization in patients with heart failure with preserved ejection fraction.
Why the study?
Specific pharmacological treatment of HFpEF remains challenging due to the lack of evidence proving a significant reduction in mortality outcomes.
This review provides a flowchart for managing HFpEF, emphasizing the treatment of associated comorbidities such as hypertension and atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Figueiredo et al. (2022) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Pharmacological treatments (SGLT2 inhibitors, RAAS inhibitors, neprilysin inhibitors, nitrates) was evaluated. Sodium-glucose cotransporter 2 inhibitors demonstrated significant benefits in reducing cardiovascular death or hospitalization in patients with heart failure with preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: